References
- Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105:628-639. https://doi.org/10.1038/bjc.2011.240.
- Dillon MT, Harrington KJ. Human papillomavirus-negative pharyngeal cancer. J Clin Oncol. 2015;33:3251-61. https://doi.org/10.1200/JCO.2015.60.7804.
- Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537-549. https://doi.org/10.1038/nrc2887.
- Pearl LH, Prodromou C. Structure, function, and mechanism of the HSP90 molecular chaperone. Adv Protein Chem. 2001; 59:157-186. https://doi.org/10.1016/S0065-3233(01) 59005-1.
- Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761-772. https://doi.org/10.1038/nrc1716.
- Neckers L. Chaperoning oncogenes: HSP90 as a target of geldanamycin. Handb Exp Pharmacol. 2006;172:259-277. https://doi.org/10.1007/3-540-29717-0_11.
- Pacey S, Banerji U, Judson I, Workman P. HSP90 inhibitors in the clinic. Handb Exp Pharmacol. 2006;172:331-358. https://doi.org/10.1007/3-540-29717-0_14.
- Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-HSP90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem. 1995;270:24585-24588. https://doi.org/10.1074/jbc.270.41.24585.
- Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, et al. Characterization of newly established oral cancer cell lines derived from six squamous cell carcinoma and two mucoepidermoid carcinoma cells. Exp Mol Med. 2005;37:379-390. https://doi.org/10.1038/emm.2005.48.
- Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med. 2001:344:1323-1326. https://doi.org/10.1056/NEJM200104263441710.
- Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A. 2002;99:12847-12852. https://doi.org/10.1073/pnas.202365899.
- Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem. 2003;278:13829-13837. https://doi.org/10.1074/jbc.m209640200.
- Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of HSP90, sensitizes human tumour cells to radiation. Int J Radiat Biol. 2003;79:973-980. https://doi.org/10.1080/09553000310001626135.
- Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun. 2006;351:658-663. https://doi.org/10.1016/j.bbrc.2006.10.094.
- Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, et al. HSP90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Oncol Rep. 2015;33:1499-1504. https://doi.org/10.3892/or.2015.3735.
- Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, et al. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014;5:2678-2687. https://doi.org/10.18632/oncotarget.1929.
- Roh J-L, Kim EH, Park HB, Park JY. The HSP90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53- mediated apoptosis in head and neck cancer. Cell Death Dis. 2013;4:e956. https://doi.org/10.1038/cddis.2013.488.
- Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. Low-dose HSP90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 2011;10:4291-4299. https://doi.org/10.4161/cc.10.24.18616.
- Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, et al. CHK1 inhibition radiosensitises head and neck cancers to paclitaxel-based chemoradiotherapy. Mol Cancer Ther. 2016;15:2042-2054. https://doi.org/10.1158/1535-7163.mct-15-0998.
- Friedman JA, Wise SC, Hu M, Gouveia C, Vander Broek R, et al. HSP90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma. Transl Oncol. 2013;6:429-441. https://doi.org/10.1593/tlo.13292.
- Suhane T, Laskar S, Advani S, Roy N, Varunan S, Bhattacharyya D, et al. Both the charged linker region and ATPase domain of HSP90 are essential for rad51-dependent DNA repair. Eukaryot Cell. 2015;14:64-77. https://doi.org/10.1128/ec.00159-14.
- Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel HSP90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010;126:1216-1225. https://doi.org/10.1002/ijc.24815.
- Stingl L, Stuhmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer. 2010;102:1578-91. https://doi.org/10.1038/sj.bjc.6605683.
- Wenjie L, Weilin A, Tony T, Anna R, Gabriela C. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener. 2010;5:24. https://doi.org/10.1186/1750-1326-5-24.
- Dillon MT, Good JS, Harrington KJ. Selective targeting of the G2/M cell cycle checkpoint to improve the therapeutic index of radiotherapy. Clin Oncol (R Coll Radiol). 2014;26:257-265. https://doi.org/10.1016/j.clon.2014.01.009.
- Zhang C-Z, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522:179-184. https://doi.org/10.1038/nature14493.
- Wang DH, Zhang YJ, Zhang SB, Liu H, Liu L, Liu FL, et al. Geldanamycin mediates the apoptosis of gastric carcinoma cells through inhibition of EphA2 protein expression. Oncol Rep. 2014;32:2429-2436. https://doi.org/10.3892/or.2014.3542.
- Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H. P53-dependent radiosensitizing effects of HSP90 inhibitor 17-Allylamino-17-demethoxy geldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol. 2006;29:1111-1117. https://doi.org/10.3892/ijo.29.5.1111.
Cited by
- Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks vol.715, pp.None, 2022, https://doi.org/10.1016/j.abb.2021.109085